RxDoctor Payments Data

Jeff Benjamin, DO

Neurology · Myrtle Beach, SCNPI 1821057779

Payments from drug & device makers

$11,315in general payments, 2019–2025

Across 717 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • AbbVie$1K
  • Acadia Pharmaceuticals Inc$1K
  • Biohaven Pharmaceuticals, Inc.$847
  • Neurocrine Biosciences, Inc.$782
  • Biohaven Pharmaceutical Holding Company Ltd.$667
  • plus $5K from 54 others

What the payments were for

  • Speaking & faculty fees$931%
  • Food & beverage$11,07498%
  • Education$1491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.118$1,624
AbbVie(2 entities)88$1,173
Acadia Pharmaceuticals Inc92$1,088
Biohaven Pharmaceuticals, Inc.43$847
Neurocrine Biosciences, Inc.37$782
Biohaven Pharmaceutical Holding Company Ltd.42$667
Novartis41$562
Amgen(2 entities)19$382
EMD Serono, Inc.20$305
UCB, Inc.12$272
Sanofi11$232
Eisai Inc.13$227
Lundbeck LLC10$212
AstraZeneca9$174
Genentech USA, Inc.9$167
Merz Pharmaceuticals, LLC6$153
Acorda Therapeutics, Inc8$149
Sunovion Pharmaceuticals Inc.11$140
Argenx US, Inc.4$128
Kyowa Kirin, Inc.8$124
Pfizer11$123
Bristol Myers Squibb7$114
Supernus Pharmaceuticals, Inc.8$110
Banner Life Sciences, LLC4$92
Otsuka America Pharmaceutical, Inc.5$91
Grifols USA, LLC5$77
CSL Behring3$75
Amneal Pharmaceuticals LLC5$68
Ipsen Biopharmaceuticals, Inc3$63
Adamas Pharmaceuticals, Inc.4$60
Neurelis, Inc.3$57
MDD US Operations, LLC4$57
Avanir Pharmaceuticals, Inc.4$57
Biogen4$56
Lilly USA, LLC4$54
Livanova USA, Inc.3$53
Scilex Pharmaceuticals Inc.3$52
Cala Health, Inc.3$52
Merz North America, Inc.2$51
Johnson & Johnson3$50
SK Life Science, Inc.2$47
GE HealthCare3$46
Mallinckrodt Enterprises LLC2$40
Upsher-smith Laboratories LLC2$39
Avion Pharmaceuticals2$33
E.r. Squibb & Sons, L.L.C.2$30
Takeda Pharmaceuticals U.S.A., Inc.1$28
ANI Pharmaceuticals, Inc.1$25
Apria Healthcare LLC2$25
TG Therapeutics, Inc.1$25
Hospira, Inc.1$23
Akcea Therapeutics, Inc.1$23
Jazz Pharmaceuticals Inc.1$18
Tanabe Pharma America, Inc.1$17
Aquestive Therapeutics, Inc.1$16
Assertio Therapeutics, Inc.1$14
Impel Pharmaceuticals Inc.1$14
Boston Scientific1$13
Abbott1$12
Zyla Life Sciences, Inc.1$11

How this compares

$11,315 in reported general payments places this provider in the 75th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$308,555
Medicare patients
1,105
Services billed
15,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe236$213,493
Kesimpta PenOfatumumab23$195,992
MayzentSiponimod12$115,047
Nurtec OdtRimegepant Sulfate75$110,466
UbrelvyUbrogepant74$94,000
Teriflunomide13$73,310
NuplazidPimavanserin Tartrate13$70,880
Memantine Hcl1,228$39,176
RexultiBrexpiprazole23$36,688
QuliptaAtogepant27$29,771
Emgality PenGalcanezumab-Gnlm34$29,584
Ajovy AutoinjectorFremanezumab-Vfrm24$25,660
KeppraLevetiracetam24$18,503
Levetiracetam350$13,737
Lacosamide193$12,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,173$123,771101 claims
NovartisMayzent$562$115,04712 claims
PfizerNurtec Odt, Dilantin$123$113,04088 claims
Acadia Pharmaceuticals IncNuplazid$1,088$70,88013 claims
Otsuka America Pharmaceutical, Inc.Rexulti$91$36,68823 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$68$17,244126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 270 neurology providers in South Carolina.

Other neurology in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →